A U.S. district court ruled in favor of AstraZeneca’s patent protection for Seroquel XR, the long-acting version of Seroquel. This follows AstraZeneca’s failure to prevent the FDA from approving generic versions of Seroquel, exposing the company to one of the largest losses to drug-patent expirations in the pharmaceutical sector. A U.K. court has denied AstraZeneca’s request for protection of Seroquel XR’s patent.
Article → Related Articles:
Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.
Mad in America has made some changes to the commenting process. You no longer need to login or create an account on our site to comment. The only information needed is your name, email and comment text. Comments made with an account prior to this change will remain visible on the site.